Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin

• Published in: Bioorganic & medicinal chemistry letters Vol. 27; no. 16; pp. 3744 - 3748
• Main Authors: Wright, Zoë V.F., Wu, Nicholas C., Kadam, Rameshwar U., Wilson, Ian A., Wolan, Dennis W.
• Format: Journal Article
• Language: English
• Published: OXFORD Elsevier Ltd 15.08.2017; Elsevier
• Subjects: Antiviral Agents - chemical synthesis; Antiviral Agents - chemistry; Antiviral Agents - pharmacology; Arbidol; Bio-layer interferometry; Chemistry; Chemistry, Medicinal; Chemistry, Organic; Crystallography, X-Ray; Dose-Response Relationship, Drug; Hemagglutinin; Hemagglutinins - metabolism; Humans; Indoles - chemical synthesis; Indoles - chemistry; Indoles - pharmacology; Influenza; Influenza, Human - drug therapy; Life Sciences & Biomedicine; Models, Molecular; Molecular Structure; Orthomyxoviridae - drug effects; Pharmacology & Pharmacy; Physical Sciences; Science & Technology; Structure-Activity Relationship; Structure-based drug design; Arbidol; Structure-based drug design; Bio-layer interferometry; Hemagglutinin; Influenza; IN-VITRO; FUSION; INHIBITION; A VIRUSES; RESISTANCE; OSELTAMIVIR
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2017.06.074

[Display omitted] Influenza is a highly contagious respiratory viral infection responsible for up to 50,000 deaths per annum in the US alone. The need for new therapeutics with novel modes of action is of paramount importance. We determined the X-ray structure of Arbidol with influenza hemagglutinin and found it was located in a distinct binding pocket. Herein, we report a structure-activity relationship study based on the co-complex combined with bio-layer interferometry to assess the binding of our compounds. Addition of a meta-hydroxy group to the thiophenol moiety of Arbidol to replace a structured water molecule in the binding pocket resulted in a dramatic increase in affinity against both H3 (1150-fold) and H1 (98-fold) hemagglutinin subtypes. Our analogues represent novel leads to yield more potent compounds against hemagglutinin that block viral entry.